Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay
Biotechnology and Bioengineering · 2025-05 · 122 (5) · 1105-1117
DOI: 10.1002/bit.28950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 10.02.2025. Verfasst von Sherin Panikulam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharma Technology, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland. Hauptthemen laut MEDLINE: Dendritic Cells, Adjuvants, Immunologic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by Novartis Pharma AG..
Abstract (Originalsprache)
Host cell proteins (HCPs) are process‐related impurities of therapeutic protein production and may affect product quality or patient safety. In clinical trials, certain HCPs (e.g., PLBL2 or CCL2) that co‐purify with the therapeutic protein have been associated with immune reactions in patients. In this study, we examined the adjuvant potential of six commonly detected HCPs from CHO cells (PRDX1, S100A4, PLBL2, CCL2, CLU, and YWHAE) using an in vitro dendritic cell (DC) maturation assay. Recombinant HCPs were expressed in CHO cells to mimic manufacturing conditions. PRDX1, S100A4, and PLBL2 caused a slight increase in the expression of maturation markers on DCs, while YWHAE, CLU, and CCL2 did not. Interestingly, CLU and CCL2 reduced the DC maturation induced by rituximab. In addition, we observed that process parameters such as elution conditions during chromatographic purification can influence HCP aggregation, which in turn can mask or enhance the intrinsic adjuvant potential of an HCP. These findings not only provide initial insights into the adjuvant potential of individual HCPs but also indicate that the quantity as well as the degree of aggregation of HCPs might influence adjuvanticity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharma Technology, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland.
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
- Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
- Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
ORCID-Profile: Hannah Morgan, Michael Gutknecht, Anette Karle, Oliver Anderka, Nicolas Lebesgue, Thomas K Villiger
Förderung
- This research was supported by Novartis Pharma AG.
Zitieren
APA
Panikulam, S., Morgan, H., Gutknecht, M., Karle, A., Rajaratnam, A., Muntwyler, J., Anderka, O., Lebesgue, N., & Villiger, T. K. (2025). Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay. Biotechnology and Bioengineering, 122(5), 1105-1117. https://doi.org/10.1002/bit.28950
Vancouver
Panikulam S, Morgan H, Gutknecht M, Karle A, Rajaratnam A, Muntwyler J, et al. Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay. Biotechnology and Bioengineering. 2025;122(5):1105-1117. doi:10.1002/bit.28950
BibTeX
@article{Panikulam2025,
author = {Panikulam, Sherin and Morgan, Hannah and Gutknecht, Michael and Karle, Anette and Rajaratnam, Atchaya and Muntwyler, Jennifer and Anderka, Oliver and Lebesgue, Nicolas and Villiger, Thomas K},
title = {Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay},
journal = {Biotechnology and Bioengineering},
year = {2025},
volume = {122},
number = {5},
pages = {1105--1117},
doi = {10.1002/bit.28950}
}
EUVIMED